LEFLUNOMIDE FOR USE IN RHEUMATOLOGY & PAEDIATRIC RHEUMATOLOGY Shared Care Protocol
|
|
- Barbra Greene
- 5 years ago
- Views:
Transcription
1 Oxfordshire Clinical Commissioning Group LEFLUNOMIDE FOR USE IN RHEUMATOLOGY & PAEDIATRIC RHEUMATOLOGY Shared Care Protocol This protocol provides prescribing and monitoring guidance for leflunomide therapy. It should be read in conjunction with the Summary of Product Characteristics (SPC) available on the BNF and Shared Care Protocol Responsibilities. BACKGROUND FOR USE Leflunomide is a disease modifying antirheumatic drug (DMARD). It should only be initiated by a rheumatologist. Its uses in this shared care protocol in adults include: Rheumatoid arthritis (licensed). It can be used as monotherapy or in combination with another DMARD 4. Psoriatic arthritis (licensed). Its uses in this shared care protocol in paediatrics include: Treatment of inflammatory disorders including Juvenile Idiopathic Arthritis, psoriatic arthritis, non bacterial osteomyelitis and uveitis. The optimum therapeutic dose of DMARDs should be achieved to minimise disease progression and joint erosions. Leflunomide is typically used to treat patients who are unable to tolerate methotrexate. It can also be used simultaneously with other medications including methotrexate and sulphasalazine to gain optimum control of disease if monotherapy is ineffective. Studies of children and young people aged 3 to 18 years have shown leflunomide to be a safe and effective alternative to methotrexate, resulting in substantial improvements in joint mobility and function in children with Juvenile Idiopathic Arthritis (Foeldvari & Wierk, 2010; Silverman et al 2005a; Silverman et al, 2005b). Since lefluomide is only licensed for adults over 18 years and is not included within the BNF for children leflunomide should only be initiated by and under the direction of a consultant paediatric rheumatologist, or a rheumatologist with an interest in paediatric rheumatology. The first dose should be prescribed by the initiating specialist, and be prescribed by them until the dose is stable and/or the GP formally agrees to shared care (as stated in the shared care responsibilities document). For all renal patients, supply of this medication will be provided in secondary care. CONTRAINDICATIONS AND PRECAUTIONS Contraindications Vaccination with LIVE vaccines Chickenpox/shingles Patients receiving leflunomide must NOT receive immunisation with LIVE vaccines. Inactivated polio is available although sub-optimal response may be seen. Remember, for paediatrics Fluenz Tetra (nasal flu vaccine) is live so should not be used. Patients suffering from chickenpox or active skin lesions in shingles, withhold leflunomide and inform rheumatologist. For those with exposure to chickenpox or shingles and no history of infection/vaccination, passive immunisation with VZIG should be carried out. Approved by APCO May of 10 Uncontrolled if printed
2 Conception and Pregnancy Breastfeeding Impaired liver function due to any cause Moderate to severe renal impairment Precautions Infection Alcohol Pulmonary infiltration /reactions Leflunomide is teratogenic and must not be given to women of child bearing potential unless reliable contraception is used. Women planning to have children should either discontinue the drug for 2 years prior to conception or have rapid removal of its active metabolite by following the washout procedure. Blood concentrations should be checked prior to planning pregnancy (see washout procedure). Men should also receive the washout procedure and use effective contraception for 3 months after stopping leflunomide prior to planning to conceive. Avoid Avoid Avoid Vigilance required in detection and treatment. Limit alcohol intake to 4-8 units per week. Acute allergic reactions can occur. Added risk when used in combination with methotrexate. Patients should be made aware of this rare complication. DOSAGE Adults Typical dosage is mg daily. There is no dose adjustment in patients over 65 years of age or those with mild renal insufficiency. A dose of 10 mg daily is usually recommended if leflunomide is used in combination with another potentially hepatotoxic DMARD, e.g. methotrexate. Leflunomide has an elimination half life of several weeks. In cases of significant adverse reactions, washout procedure to speed elimination may be necessary. Time to response is 8 to 12 weeks. Symptoms may further improve after several months. Paediatrics Leflunomide is prescribed according to weight: o <10kg 5mg once a day o 10-40kg 10mg once a day o >40kg 20mg once a day Benefit is seen after 6 to 8 weeks and improvement may continue over a further 4 to 6 months. Leflunomide is taken in tablet form and should be swallowed whole. Tablets are available as 10mg and 20mg doses. PRE-TREATMENT ASSESSMENT BY RHEUMATOLOGIST FBC, LFT, U&Es and CRP. Blood pressure for adults, if >140/90 on two consecutive readings, two weeks apart, refer back to GP for treatment of hypertension before commencing leflunomide. Children: record baseline BP Weight (to allow assessment of weight loss which may be attributable to leflunomide). Exclude possibility of pregnancy A baseline chest X-Ray is not required unless pre-existing fibrotic or interstitial lung disease. Approved by APCO May of 10 Uncontrolled if printed
3 ONGOING MONITORING SCHEDULE FBC, U&Es, CRP, LFTs, BP, weight: Monitor fortnightly for 3 months. After that monitor monthly until stable, then reduce to every two months on specialist s advice. The monitoring interval needs to be reduced to monthly if leflunomide is used in combination with other potentially hepatotoxic agents, e.g. methotrexate. ACTIONS TO BE TAKEN Adults Side effects ADULTS WBC < 3.5 X 10^9/l Neutrophils <2 X 0^9/l Platelets <150 X 10^9/l Liver function > 2 fold rise in AST/ALT (from upper limit of reference range) Actions ADULTS Stop leflunomide and repeat WBC. If repeat count is normal continue, if abnormal discuss with specialist team. Stop leflunomide and repeat WBC. If repeat count is normal continue, if abnormal discuss with specialist team. Strict monitoring of LFT s is essential due to hepatotoxicity. Caution is necessary when used concomitantly with other hepatotoxic medication e.g. methotrexate, or if evidence current or recent hepatitis B or C infection. If on 20mg/day reduce dose to 10mg/day. Recheck weekly until normalised and maintain at 10mg/day. If ALT/AST remains elevated withhold until discussed with specialist rheumatology team. If persistent consider washout AST/ALT > 3 fold rise from upper limit of reference range Renal Impairment. i.e. egfr <30 mls minute Stop drug. Re-check LFTs within 72 hours. If persistent consider washout. Reduce dose by 50% Increase frequency of monitoring Hypertension If B/P > 140/90 Treat according to NICE guidance. If B/P remains uncontrolled, discontinue drug. Discuss with specialist team any patient not responding to treatment. Rash or severe mouth ulcers Consider dose reduction with or without antihistamines. If severe stop and consider washout procedure, Severe sore throat, abnormal Immediate FBC and withhold until result of FBC bruising available GI upset/nausea, diarrhoea Is not uncommon, usually settles, but if severe may require reduction in dose/discontinuation of the drug with or without washout procedure. Weight loss If greater than 10% with no identified cause, reduce or discontinue with or without washout. Headache If severe consider dosage reduction Alopecia Most cases are mild/ moderate and resolve during treatment. If severe consider dosage reduction Tenosynovitis and rarely Discuss with specialist team. tendon rupture.. Approved by APCO May of 10 Uncontrolled if printed
4 Paediatric Side Effect PAEDIATRIC WBC < 4 X 10^ 9 /l Neutrophils <1.5 X10^9/l Platelets <150 X10^9/l Liver function. ALT or AST >120 MCV > 105 fl Hypertension Rash or severe oral ulceration Unexplained fall in Albumin Diarrhoea Significant reduction in renal function Weight loss Alopecia Actions PAEDIATRIC Withhold, repeat WBC, if normal continue, otherwise discuss with paediatric rheumatology team Withhold until discussed with paediatric rheumatology team Withhold until discussed with paediatric rheumatology team Withhold until discussed with paediatric rheumatology team. Transaminase increase 3 X normal is common within 2 days of drug administration and may be attributable to an asymptomatic viral infection. Consider rechecking ALT at trough level. (i.e 0-2 days prior to injection) Check folate. GGT, TSH B12. If B12 or folate low, start appropriate supplementation. See Appendix A for normal blood pressures in children. Recheck any blood pressures above 90 th centile in 1 week. If above 95 th centile for 3 consecutive weeks then discuss with paediatric rheumatology team. Look for alternative causes. Withhold until discussed with paediatric rheumatology team. Re-challenge with lower dose once symptoms settle. Withhold until discussed with rheumatologist Monitor to ensure caused by leflunomide and not gastroenteritis. Discuss with paediatric rheumatology team if continues to be a problem. Consider alternative causes, reduce dose following discussion with paediatric rheumatologist. If greater than 10% with no identified cause discuss with the paediatric rheumatology team. Most cases are mild/ moderate and resolve during treatment. If severe consider dosage reduction. Usually reversible if attributable to leflunomide Please note that in addition to absolute values for haematological indices, a rapid fall or a consistent downward trend in any value should prompt caution and extra vigilance. In order to monitor trends it is recommended that all blood test results are entered in the patient held monitoring booklet. Note: Annual flu vaccination is recommended (warning: do not use the live paediatric nasal spray) Leflunomide can be withheld for 2-3 weeks without inducing a flare. Leflunomide should not be stopped prior to elective surgery. WASHOUT PROCEDURE ADULTS: This is used to aid drug elimination in case of significant adverse effect, or before starting another DMARD or before conception (for both men and women planning a pregnancy). Refer back to Rheumatology for washout. Stop leflunomide then use either: Cholestyramine 8g 3 times daily for a period of 11 days Or 50 g of activated charcoal 4 times daily for a period of 11 days. (aperient is recommended ) Approved by APCO May of 10 Uncontrolled if printed
5 For both men and women before conception 2 blood tests are required at least 14 days apart to check plasma levels, which must drop below 0.02mg/l. A waiting period of one-and-a-half months between the first plasma reading below 0.02mg/l and fertilisation is required. WASHOUT PROCEDURE PEDIATRICS The paediatric rheumatology team will advise if a washout procedure is required. It is recommended that patients requiring the washout procedure should be referred back to the paediatric rheumatology team. After stopping Leflunomide use either: Cholestyramine: o 1 6 years 2g once daily for a period of 11 days o 6 12 years 4g once daily for a period of 11 days o years 4 8g once daily for a period of 11 days Or Activated Charcoal: o Activated Charcoal 1g/kg (max 50g) administered 4 times daily for a period of 11 days. In addition 2 blood tests are required at least 14 days apart to check plasma levels, which must drop below 0.02mg/l. NOTABLE DRUG INTERACTIONS Other haematotoxic and hepatotoxic drugs, e.g. methotrexate: Reduce monitoring interval. Warfarin: Plasma levels may be increased by leflunomide. Monitor INR of warfarin treated patients closely. Phenytoin: Plasma levels may be increased by leflunomide. Monitor phenytoin plasma levels of leflunomide treated patients. Tolbutamide: Hypoglycaemic effects may be increased by leflunomide. Rifampicin: Increases leflunomide plasma levels. NSAIDs may be used. Leflunomide has an extremely long elimination half-life and interactions with these drugs may continue for at least eight weeks after leflunomide has been discontinued. BACK-UP INFORMATION/ADVICE Contact Details Rheumatology Medicines Information Mylan ad hoc Advisory Service (information on plasma level laboratory testing) Free Plasma Level Testing Oxford University Hospitals NHS Trust Rheumatology Helpline (Adult and Paediatric) Rheumatology Senior Registrar on call Tel (0) (option 1) , ask for SR on call via switchboard. Sponsored by Sanofi-Aventis. The kits and testing are provided by Eurofins Medinet. To obtain a kit order form contact Sanofi-Aventis Medicines Information on Approved by APCO May of 10 Uncontrolled if printed
6 REFERENCES 1. NICE Clinical Guideline 34 Hypertension, June BNF 68. Sept 2014 Mar Leflunomide SPC, 4. NICE Clinical Guideline 79, Rheumatoid Arthritis, April 2009 Acknowledge: Adapted from Buckinghamshire CCG Shared Care Protocols Approved by APCO May of 10 Uncontrolled if printed
7 APPENDIX A Approved by APCO May of 10 Uncontrolled if printed
8 Approved by APCO May of 10 Uncontrolled if printed
9 Approved by APCO May of 10 Uncontrolled if printed
10 (2004)The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents.Pediatrics. Aug;114(2 Suppl 4th Report):p Approved by APCO May of 10 Uncontrolled if printed
Duration of treatment All DMARDs are long term treatments. Clinical benefit may take up to 6 months. 1
Leflunomide Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti Rheumatic
More informationLeflunomide (Arava )
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationTrust-wide Guideline
Trust-wide Guideline For Shared Care Guidelines for the Use of Leflunomide (Arava ) A guideline recommended for use In: East and North Herts NHS Trust (ENHT) East and North Herts PCT/ENHCCG By: Consultants
More informationShared Care Guideline Stepping Hill Hospital and North Derbyshire CCG
Shared Care Guideline Stepping Hill Hospital and North Derbyshire CCG Rheumatological Conditions in Adults Reference Number Replaces: Issue date: November 2017 Author(s)/Originator(s): (please state author
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationProducts available Methotrexate tablets 2.5mg ONLY (Methotrexate tablets 10mg are NOT recommended as per NPSA guidance 5 ).
Methotrexate Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationShared Care Guideline: Leflunomide
Basingstoke, Winchester & Southampton District Prescribing Committee Shared Care Guideline: Leflunomide Name of patient treated under this guideline: This shared care guideline has been produced to support
More informationSHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Drug: Methotrexate Introduction Indication: Licensed: Rheumatoid arthritis, severe psoriasis, severe active juvenile idiopathic arthritis, severe psoriatic arthritis, mild to moderate
More informationAzathioprine Shared Care Guideline for GPs
Indication: Azathioprine Shared Care Guideline for GPs Active rheumatoid arthritis and other types of inflammatory arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, vasculitis
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED
More informationSHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationNORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE
NORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE http://www.devonpct.nhs.uk/treatments/ne_devon_shared_care_guidelines.aspx#a Azathioprine Treatment of rheumatological conditions
More informationGreater Manchester Interface Prescribing Group Shared Care Template
Greater Manchester Interface Prescribing Group Shared Care Template Shared Care Guideline for Oral Methotrexate for Rheumatological Conditions Author(s)/Originator(s): (please state author name and department)
More informationShared Care Protocol Responsibilities
Oxfordshire Clinical Commissioning Group AZATHIOPRINE FOR USE IN RHEUMATOLOGY, DERMATOLOGY, GASTROENTEROLOGY LIVER, NEUROLOGY, RESPIRATORY AND RENAL Shared Care Protocol This protocol provides prescribing
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationWestern Locality Shared care Information ~ Penicillamine, Rheumatology April 2013
Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to
More informationSHARED CARE AGREEMENT: METHOTREXATE S/C
NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) and BSR Guideline for disease-modifying anti-rheumatic drug (DMARD) therapy (available at www.rheumatology.org.uk/resources/guidelines/bsr_guidelines.aspx
More informationShared Care Protocol Responsibilities
Oxfordshire Clinical Commissioning Group METHOTREXATE FOR USE IN RHEUMATOLOGY (ADULT AND PAEDIATRIC), DERMATOLOGY, NEUROLOGY, GASTROENTEROLOGY, OPHTHALMOLOGY AND RESPIRATORY MEDICINE Shared care protocol
More informationShared Care Protocol Responsibilities
Oxfordshire Clinical Commissioning Group CICLOSPORIN FOR USE IN DERMATOLOGY, RHEUMATOLOGY, NEUROLOGY and GASTROENTEROLOGY Shared Care Protocol This protocol provides prescribing and monitoring guidance
More informationEast Lancashire Medicines Management Board Shared Care agreement for weekly Methotrexate therapy in long term conditions
East Lancashire Medicines Management Board Shared Care agreement for weekly Methotrexate therapy in long term conditions This shared care agreement outlines the responsibilities for managing the prescribing
More informationRheumatology Shared Care Guidelines
Rheumatology Shared Care Guidelines 1. Introduction Rheumatoid Arthritis (RA) is a chronic, progressive inflammatory disease of the synovial lining of peripheral joints. The goals of management of RA are
More informationCiclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml
Shared Care Protocol Ciclosporin for the treatment of rheumatoid arthritis Name of drug, form and strength Background Ciclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml Ciclosporin
More informationDMARDS MONITORING GUIDELINES SELKIRK MEDICAL PRACTICE
DMARDS MONITORING GUIDELINES SELKIRK MEDICAL PRACTICE LIST OF DRUGS INCLUDED: ACITRETIN (Neotigason) ADALIMUMAB AMIODARONE AMISULPIRIDE ARIPRAZOLE AZATHIOPRINE CICLOSPORIN CYCLOPHOSPHAMIDE CLOZAPINE DENOSUMAB
More informationShared Care Guideline Stepping Hill Hospital and North Derbyshire CCG
Shared Care Guideline Stepping Hill Hospital and North Derbyshire CCG Shared Care Guideline for Sulfasalazine in Rheumatological Conditions in Adults Reference Number Replaces: Issue date: November 2017
More informationAzathioprine and Mercaptopurine
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationWestern Locality Shared care information ~ Azathioprine and Mercaptopurine
The following guidelines are currently under review. In the interim, the guidelines remain valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they
More informationESCA: All non-biological DMARDs (oral/subcutaneous) and agreement for transferring of DMARD Prescribing & Monitoring to GP
ESCA: All non-biological DMARDs (oral/subcutaneous) and agreement for transferring of DMARD Prescribing & Monitoring to GP Dermatology/ Haematology/ Gastroenterology/ Neurology/ Ophthalmology/ Respiratory/
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationSUMMARY OF SHARED CARE PROTOCOL FOR MYCOPHENOLATE MOFETIL (MMF)
SUMMARY OF SHARED CARE PROTOCOL FOR MYCOPHENOLATE MOFETIL (MMF) Please refer to Chester Rheumatology shared care protocol for MMF and separate responsibilities document for full details. Responsibilities
More informationMETHOTREXATE (Adults)
Shared Care Guideline Methotrexate (Adults) Contents Introduction:... 1 Contraindications & Warnings:... 2 Interactions:... 3 Adverse Effects:... 3 Responsibilities of the specialist initiating treatment:...
More informationName of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008
Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately
More informationNHS Suffolk Shared Care Guidelines for the Treatment of Rheumatoid Arthritis with LEFLUNOMIDE
Suffolk Drug & Therapeutics Committee NHS Suffolk Shared Care Guidelines for the Treatment of Rheumatoid Arthritis with LEFLUNOMIDE What is a shared care document? Suffolk D&T operates a traffic light
More informationPrescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More informationWestern Locality Shared care Information ~ Methotrexate, Rheumatology April 2013
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationLeflunomide Treatment Rheumatology Patient Information Leaflet
Leflunomide Treatment Rheumatology Patient Information Leaflet Originator: Dr K Douglas Date: September 2011 Version: 2 Date for Review: September 2014 DGOH Ref No: DGOH/PIL/00217 Contact numbers If your
More informationShared Care Guideline Stepping Hill Hospital and North Derbyshire CCG
Shared Care Guideline Stepping Hill Hospital and North Derbyshire CCG Rheumatological Conditions in Adults Reference Number Replaces: Issue date: November 2017 Author(s)/Originator(s): (please state author
More informationHYDROXYCARBAMIDE for Haematological conditions (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: HYDROXYCARBAMIDE for Haematological conditions (Adults) Indication: Hydroxycarbamide is an established treatment in haematological
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationShared Care Agreement Methotrexate Oral and Subcutaneous For the use in gastroenterology, dermatology and rheumatology
Shared Care Agreement Methotrexate Oral and Subcutaneous For the use in gastroenterology, dermatology and rheumatology Principles of Shared Care Shared care is the mechanism of sharing patient care between
More informationTreatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis
Treatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis This protocol provides monitoring guidance for adult patients requiring Dimethyl fumarate therapy
More informationPRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD)
PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD) For the latest information on interactions and adverse effects, always consult the latest version of the Summary of
More informationShared Care Protocol Oral methotrexate 2.5mg tablets in dermatology/gastroenterology/rheumatology patients
Shared Care Protocol Oral methotrexate 2.5mg tablets in dermatology/gastroenterology/rheumatology patients Specialist Details Name: Patient Identifier (please include NHS number as minimum) Location: Telephone
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: AZATHIOPRINE Protocol number: CV 04
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: AZATHIOPRINE Protocol number: CV 04 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION LIVER
More informationMethotrexate for inflammatory bowel disease: what you need to know
Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or
More informationWeekly oral and subcutaneous methotrexate
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationShared Care Guideline. Prescribing and Monitoring of oral METHOTREXATE in adults Licensed and off-label indications
North Central London Joint Formulary Committee Shared Care Guideline Prescribing and Monitoring of oral METHOTREXATE in adults Licensed and off-label indications Dear GP, Progressing to a stable, optimal
More informationWORKING IN PARTNERSHIP WITH
WORKING IN PARTNERSHIP WITH Brighton and Hove Clinical Commissioning Group Crawley Clinical Commissioning Group Horsham and Mid Sussex Clinical Commissioning Group High Weald Lewes Havens Clinical Commissioning
More informationShared care guidelines for azathioprine in adults. General principles. Presentation/Dose/Administration Oral: 25mg and 50mg tablets
Shared care guidelines for azathioprine in adults General principles This agreement outlines suggested ways in which the responsibilities for managing the prescribing of the drug treatment and clinical
More informationEffective Shared Care Agreement (ESCA)
Effective Shared Care Agreement (ESCA) Azathioprine (either alone or more usually in combination with corticosteroids and/or other drugs and procedures) ESCA: For the treatment of systemic lupus erythematosus
More informationV4.1 Amendment to hydroxychloroquine ophthalmology monitoring made. Agreed by Camden Medicines Management Committee: October 2017 August 2017
North Central London Joint Formulary Committee Quick Reference Guide for Primary Care Prescribers Monitoring Disease Modifying Anti-Rheumatic Drugs (DMARDs) Azathioprine, Mercaptopurine, Sulfasalazine,
More informationPRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis
PRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis For the latest information on interactions and adverse effects, always consult the latest version of the Summary of Product Characteristics
More informationCiclosporin for Rheumatology and Dermatology use (Adults)
Shared Care Guideline Ciclosporin for Rheumatology and Dermatology use (Adults) Introduction This shared care agreement outlines the responsibilities between the specialist and the generalist for managing
More informationGreater Manchester Interface Prescribing Group Shared Care Template
Greater Manchester Interface Prescribing Group Shared Care Template Shared Care Guideline for Azathioprine and 6-Mercaptopurine for Chronic Inflammatory Bowel Disease Author(s)/Originator(s): (please state
More informationORAL CICLOSPORIN RHEUMATOLOGY LOCAL SAFETY MONITORING SCHEDULE
ORAL CICLOSPORIN RHEUMATOLOGY LOCAL SAFETY MONITORING SCHEDULE This local safety-monitoring schedule supports clinicians under the Local Enhanced Service for High Risk Drug Monitoring (formerly Near Patient
More informationShared Care Guideline
Shared Care Guideline Mercaptopurine inflammatory bowel disease Executive Summary Unlicensed indication, but widely established use of mercaptopurine. Dosing: 25mg daily for two weeks, then 1-1.5mg/kg
More informationTocilizumab Tocilizumab
Drug information Tocilizumab Tocilizumab This leaflet provides information on tocilizumab and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets
More informationWeekly oral and subcutaneous methotrexate
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationEMEA PUBLIC STATEMENT ON LEFLUNOMIDE (ARAVA) - PANCYTOPENIA AND SERIOUS SKIN REACTIONS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 25 October 1999 EMEA/31637/99 EMEA PUBLIC STATEMENT ON LEFLUNOMIDE (ARAVA) - PANCYTOPENIA AND
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti-Cancer Treatment Protocol. Abiraterone. PROCTOCOL REF: MPHAABIRA (Version No: 1.
Systemic Anti-Cancer Treatment Protocol Abiraterone PROCTOCOL REF: MPHAABIRA (Version No: 1.0) Approved for use in: The treatment of metastatic castration resistant prostate cancer in adult men who are
More informationNational Neuromyelitis Optica Service
England For Highly Specialised Service National Neuromyelitis Optica Service METHOTREXATE Medication Information This information leaflet is designed to answer common questions patients ask about Methotrexate.
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple
More information. AREAS OF RESPONSIBILITY FOR SHARED CARE
SHARED CARE GUIDELINE FOR RILUZOLE IN THE MANAGEMENT OF MOTOR NEURONE DISEASE (MND) SPECIFICALLY AMYOTROPHIC LATERAL SCLEROSIS (ALS) INDICATION This shared care guideline has been prepared to support the
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA)
EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: HYDROXYCHLOROQUINE INDICATION/S COVERED: active rheumatoid arthritis, juvenile idiopathic arthritis, discoid and systemic lupus erythematosus Coastal West
More informationMETHOTREXATE POLICY. Care of Patients who are taking Methotrexate in Low Immunosuppressant Doses (e.g. weekly oral / s/c / or i/m doses)
METHOTREXATE POLICY Care of Patients who are taking Methotrexate in Low Immunosuppressant Doses (e.g. weekly When using this document please ensure that the version you are using is the most up to date
More informationMethotrexate Methotrexate.indd 1 9/1/16 11:40 AM
Methotrexate 110465 Methotrexate.indd 1 9/1/16 11:40 AM This leaflet only provides information for patients being treated with methotrexate (25mg or less per week). About your medicine Methotrexate is
More informationShared care guidelines for hydroxychloroquine for rheumatoid arthritis and other rheumatological conditions in adults.
Shared care guidelines for hydroxychloroquine for rheumatoid arthritis and other rheumatological conditions in adults. General Principles This agreement outlines suggested ways in which the responsibilities
More informationINFLIXIMAB PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY
INFLIXIMAB PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY 1. Background and indications Infliximab is a drug that blocks a key protein of all inflammatory processes called Tumour Necrosis Factor (or TNF). TNF is
More informationIf your IBD has not been well controlled, or is flaring up quite often, methotrexate may be added to your treatment.
Patient Information Drugs for Inflammatory Bowel Disease Methotrexate Clinical Nurse Specialist - Allyson Lewis Clinical Nurse Specialist Gareth Lloyd-Ford Nurse Specialist Lynsey Hook If your IBD has
More informationDimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients
Dimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients Author and Contact details: Responsible Director: Ian Pomeroy Service lead for MS. Tel: (0151) 529 5715 Email: ian.pomeroy@thewaltoncentre.nhs.uk
More informationShared Care Guideline
Shared Care Guideline Thiopurine treatment for paediatric gastroenterology and hepatology patients 1. Scope Prescribing and monitoring of thiopurine treatment of Paediatric gastroenterology and hepatology
More informationAbatacept. What is abatacept?
What is abatacept? Abatacept (trade name Orencia) is a type of drug called a biological therapy. It works by stopping the function of a particular cell in the immune system (called a T-cell). This prevents
More informationVandetanib. ICD-10 codes Codes with a pre-fix C73.
Vandetanib Indication First line treatment of histologically confirmed, unresectable, locally advanced or metastatic medullary thyroid cancer in patients with progressive and symptomatic disease. ICD-10
More informationFAMILY PLANNING AND AUBAGIO (teriflunomide)
FAMILY PLANNING AND AUBAGIO (teriflunomide) INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. IMPORTANT SAFETY INFORMATION WARNING:
More informationSHARED CARE ARRANGEMENT for DMARDs
SHARED CARE ARRANGEMENT for DMARDs Azathioprine, Ciclosporin, Leflunomide, Mercaptopurine, Methotrexate, Mycophenolate Mofetil, Penicillamine and Sulfasalazine Version: Date: Author: Status: Comment: 1.2
More informationDrug information. Tofacitinib TOFACITINIB. is used to treat rheumatoid arthritis and psoriatic arthritis. Helpline
Drug information Tofacitinib TOFACITINIB is used to treat rheumatoid arthritis and psoriatic arthritis Helpline 0800 5200 520 1 Introduction Tofacitinib is a drug that can help prevent your condition causing
More informationMethotrexate Treatment Rheumatology Patient Information Leaflet
Methotrexate Treatment Rheumatology Patient Information Leaflet Originator: Dr R Klocke, Consultant Rheumatologist and Sr Stephanie Mole, CNS Date: Sept 2011 Version: 1 Date for Review: Sept 2011 DGOH
More informationTOFACITINIB PATIENT INFORMATION ON. (Brand name: Xeljanz ) What is tofacitinib? Important things to remember
PATIENT INFORMATION ON TOFACITINIB (Brand name: Xeljanz ) This information sheet has been produced by the Australian Rheumatology Association to help you understand the medicine that has been prescribed
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: MYCOPHENOLATE MOFETIL/SODIUM Protocol number: CV 15
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: MYCOPHENOLATE MOFETIL/SODIUM Protocol number: CV 15 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION
More informationWe will review the need for continuing treatment with you after 3 months and again after one year.
Patient Information Drugs for Inflammatory Bowel Disease Adalimumab (Humira) Clinical Nurse Specialist - Allyson Lewis Clinical Nurse Specialist Gareth Lloyd-Ford Clinical Nurse Specialist Lynsey Hook
More informationMyocrisin (gold) injections. Rheumatology Department Patient Information Leaflet
Myocrisin (gold) injections Rheumatology Department Patient Information Leaflet Please keep this information in a safe place Introduction Myocrisin is in a family of drugs called disease modifying antirheumatic
More informationInflammatory arthritis Shared Decision Making
Inflammatory arthritis Shared Decision Making DMARDs El Miedany et al. Ann Rheum Dis 74(Suppl2): 1002 DOI: 10.1136/annrheumdis-2015-eular.1410 www.rheumatology4u.com Copyrights reserved Contents 1 2 3
More informationSunitinib (renal) ICD-10 codes Codes with a prefix C64
Sunitinib (renal) Indication First line treatment of patients with advanced and/or metastatic renal cell carcinoma who are suitable for immunotherapy and have an Eastern Cooperative Oncology Group (ECOG)
More informationMethotrexate. Information for patients. Paediatric Rheumatology. Feedback
Feedback We appreciate and encourage feedback. If you need advice or are concerned about any aspect of care or treatment please speak to a member of staff or contact the Patient Advice and Liaison Service
More informationShared Care Guideline
Shared Care Guideline Ciclosporin (Neoral ) in inflammatory bowel disease Executive Summary Unlicensed indication, but widely established use of ciclosporin. Starting dose of 5-8mg/kg (in twice daily divided
More informationPrescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant Patient s Name:.. NHS Number: Patient s Address:...
More informationCapecitabine Oxaliplatin 21 day cycle (XELOX)
Systemic Anti Cancer Treatment Protocol Capecitabine Oxaliplatin 21 day cycle (XELOX) PROTOCOL REF: MPHAXELOX (Version No: 1.0) Approved for use in: Adjuvant colorectal cancer stage 3 or high risk stage
More informationPrescribing Framework for Ciclosporin Post Solid Organ Transplant
Hull & East Riding Prescribing Committee Prescribing Framework for Ciclosporin Post Solid Organ Transplant Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationBreast Pathway Group FEC75 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer
Breast Pathway Group FEC75 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant therapy in early breast cancer Regimen details: Fluorouracil 600mg/m
More information- Active rheumatoid arthritis in adult patients where treatment with disease modifying antirheumatic drugs (DMARD) is indicated.
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) TREXAN 25 MG/ML, SOLUTION FOR INJECTION, PRE-FILLED SYRINGE ORION CORPORATION DATE: 12-01-2015, VERSION 1.2 VI.2 Elements for a Public Summary Methotrexate
More informationUnderstanding Methotrexate
Understanding Methotrexate Turnberg Building Inflammatory Bowel Disease Service 0161 206 4023 All Rights Reserved 2018. Document for issue as handout. What is my medication? Methotrexate is considered
More informationAbatacept Drug information. Abatacept is used to treat rheumatoid arthritis.
Abatacept Drug information Abatacept is used to treat rheumatoid arthritis. Abatacept should effectively treat your condition, and stop it causing damage to your joints. It has been tested and has helped
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: AZATHIOPRINE INDICATION/S COVERED: FOR RHEUMATOLOGY AND DERMATOLOGY
WORKING IN PARTNERSHIP WITH Coastal West Sussex Traffic Light system classification: Amber N.B. The eligibility criteria included here apply to new patients commencing treatment under this agreement &
More informationDenosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures
APper apc15-0avgfh7 Shared Care Guideline Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures For the latest information on interactions and adverse effects,
More informationKELFER Deferiprone. COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg
KELFER Deferiprone COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg KELFER-500 Capsules Each capsule contains Deferiprone 500 mg DOSAGE FORM Capsules PHARMACOLOGY Pharmacodynamics
More informationCOUNTY DURHAM AND DARLINGTON NHS FOUNDATION TRUST DEPARTMENT OF RHEUMATOLOGY
COUNTY DURHAM AND DARLINGTON NHS FOUNDATION TRUST DEPARTMENT OF RHEUMATOLOGY MANAGEMENT OF DISEASE MODIFYING ANTI-RHEUMATIC DRUG THERAPY (DMARD BLOOD MONITORING) SHARED CARE PROTOCOL A GUIDE FOR PRIMARY
More informationMethotrexate. Patient Educational Guide RHEUMATOLOGY
Methotrexate Patient Educational Guide RHEUMATOLOGY 2 Introduction This educational booklet has been prepared to help you understand more about methotrexate. Decisions about your treatment must be made
More informationCabozantinib (Cabometyx )
Cabozantinib (Cabometyx ) Indication Treatment of advanced renal cell carcinoma following prior vascular endothelial growth factor (VEGF) targeted therapy. (NICE TA463) Treatment of previously untreated
More information